Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

The goal of the collaboration is to evaluate ivonescimab, in combination with several unique Pfizer ADCs across multiple ... assets in the fields of cancer, autoimmune disease, inflammation ...

Pfizer also launched a transformative treatment for alopecia areata – an autoimmune disease causing ... Yalcinkaya shared: “We worked in close collaboration with governments and healthcare ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201. DR-0201 is ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include younger adults, and announced a collaboration with Flagship Pioneering for ...